Anemia in Heart Failure: A Perspective from 20-Year Bibliometric Analysis

Qiwen Yang1,2, Tairan Dong1, Diyang Lyu2

  • 1Graduate School, Beijing University of Chinese Medicine, Beijing, People's Republic of China.

Insights

This bibliometric analysis reveals a steady growth in research on anemia in heart failure (HF). Future research should focus on intravenous iron and iron deficiency to improve patient outcomes.

Area of Science:

  • Cardiology
  • Hematology
  • Bibliometrics

Background:

  • Anemia in heart failure (HF) is a growing clinical concern.
  • No previous bibliometric analyses have been conducted in this specific research area.
  • Understanding the research landscape is crucial for advancing patient care.

Purpose of the Study:

  • To conduct a bibliometric analysis of research on anemia in heart failure (HF).
  • To identify the status, trends, and influential contributors in the field.
  • To provide an outlook on future research directions.

Main Methods:

  • Publications were retrieved from the Web of Science Core Collection (2004-2023).
  • Data analysis and visualization were performed using VOSviewer, CiteSpace, Scimago Graphica, Biblimatrix, and Microsoft Excel.
  • Bibliometric indicators including countries, authors, institutions, journals, co-citations, and keywords were analyzed.

Main Results:

  • A total of 3490 publications were identified, showing steady growth.
  • The United States, United Kingdom, and Italy led in publications; Stefan D Anker was the most influential author.
  • Key research areas included mortality, outcome, prevalence, and risk, with future hotspots identified as intravenous iron and iron deficiency.

Conclusions:

  • This bibliometric analysis offers a comprehensive overview of the research landscape concerning anemia in heart failure.
  • The findings highlight current trends and identify key players and influential works.
  • Future research should explore comprehensive treatment approaches and management targets, particularly focusing on iron interventions.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
573
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
367